RTP Mobile Logo
Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2021 ASCO Annual Meeting (Audio Program)
Released July 2021

Featuring an interview with Dr Sara Tolaney. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

    LEARNING OBJECTIVES

    • Evaluate published research data for guidance in the selection and duration of neoadjuvant, adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
    • Incorporate existing and recently approved anti-HER2 therapies in a long-term clinical plan for the management of metastatic HER2-positive breast cancer.
    • Recognize common and rare side effects associated with novel anti-HER2 agents, and develop supportive management plans for patients with HER2-positive breast cancer receiving these therapies.
    • Assess available clinical trial findings with CDK4/6 inhibitors and PI3 kinase inhibitors for ER-positive metastatic breast cancer, and consider patient- and disease-related factors to individualize the selection and sequence of systemic therapy.
    • Recall available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in patients with localized triple-negative breast cancer, and determine the current and potential role of these strategies in clinical practice.
    • Assess potential biomarkers of response to PARP inhibition, and use this information to optimize the selection of available genetic testing platforms and related therapeutic interventions for patients with breast cancer.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Sara M Tolaney, MD, MPH
    Associate Director, Susan F Smith Center for Women’s Cancers
    Director of Clinical Trials, Breast Oncology
    Director of Breast Immunotherapy Clinical Research
    Senior Physician
    Breast Oncology Program
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: 4D pharma plc, AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Certara, Chugai Pharmaceutical Co Ltd, CytomX Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Ellipses Pharma, G1 Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, Kyowa Kirin Co Ltd, Lilly, Merck, Mersana Therapeutics, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, OncoSec Medical, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Data and Safety Monitoring Board/Committee: Odonate Therapeutics.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Novartis and Puma Biotechnology Inc.

    Release date: July 2021
    Expiration date: July 2022

Acknowledge and close

Listen to program
(WIFI is recommended for best performance):